Abstract
Commentary: Torpor: The Rise and Fall of 3-Monoiodothyronamine from Brain to Gut-From Gut to Brain?
Highlights
In this issue of Frontiers in Endocrinolgy, Glossman and Lutz present an interesting review of the pharmacological effects of 3-iodothyronamine (T1AM) reported in literature questioning the relevance of T1AM hibernating activity
Glossman and Lutz smartly discuss, in particular, the reasons why T1AM cannot be proposed as an hibernating agent pointing the reader’s attention to the following simple observations: (i) the torpor like effect is obtained administering very high doses of T1AM, (ii) it is known that T1AM, is a multi-target molecule, in virtue of its chemical structure, and the hibernating effect cannot result from activation of trace amine associated receptors, and (iii) because of its poor pharmacokinetic properties, T1AM needs to be administered at high doses, inevitably exposing the subject to the risk of side effects
Before discarding any knowledge surrounding T1AM, we would like to underline some recent studies that suggest that pharmacokinetic is essential for the manifestation of T1AM pharmacological effects when administered at very low doses
Summary
In this issue of Frontiers in Endocrinolgy, Glossman and Lutz present an interesting review of the pharmacological effects of 3-iodothyronamine (T1AM) reported in literature questioning the relevance of T1AM hibernating activity. Pharmacological effects of the amine are discussed in the context of its pharmacodynamic and pharmacokinetic properties.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
